medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number S1

<< Back Next >>

Ann Hepatol 2006; 5 (S1)

Module XVll
Treatment of hepatitis C before and after liver transplantation

Moreno AR

Language: English
References: 35
Page: 63-66
PDF size: 41.66 Kb.


Text Extraction

Liver cirrhosis secondary to chronic hepatitis C virus (HCV) infection is the primary reason for transplantations in most centers. Despite a reduction in the incidence of hepatitis C, the number of HCV-positive individuals with end-stage liver disease is expected to increase. Factors responsible for this trend include the development of cirrhosis in one third of HCV patients after 25–35 years of infection, the high prevalence of HCV in people aged 30–50 years, and the lack of an effective treatment for hepatitis C.


REFERENCES

  1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-78.

  2. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9(Suppl.3): S1-S9.

  3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9(Suppl.3): S28-S34.

  4. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl 3): S58-S62.

  5. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.

  6. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.

  7. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-74.

  8. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.

  9. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.

  10. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41.

  11. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32: 852-8.

  12. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-56.

  13. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl 2003; 9(Suppl.3): S44-S47.

  14. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9(Suppl.3): S58-S62.

  15. McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003; 9(Suppl.3): S21-S27.

  16. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63-S66.

  17. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol 2005; 42: 456-62.

  18. Crippin JS, Sheiner P, Terrault NA, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 2002; 8: 350-5.

  19. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9(Suppl.3): S90-S94.

  20. Thomas RM, Brenns JJ, Guzmán-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.

  21. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.

  22. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus infected patients undergoing liver transplantation. Liver Transpl 2003; 9: S95-S100.

  23. Sheiner P, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-38.

  24. Singh N, Gayowski T, Wannstedt C, Shakil O, Wagener M, Fung J, et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65: 82-6.

  25. Mazzaferro V, Tagger A, Schiavo M, Regalia A, Pulvirenti M, Ribero J, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001; 33: 1355-7.

  26. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher N, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. Am J Transpl 2005; 5: 118-124.

  27. Berenguer M, Prieto M, Palau A, Carrasco D, Rayon JM, Calvo F, Berenguer J. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16(11): 1207-12.

  28. Ross AS, Bhan AK, Pascual M, Thiim M, Cosimi AB, Chung RT. Pegylated interferon alfa-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18: 166-73.

  29. Dumortier J, Scoaxec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa 2b and ribavirin combination. J Hepatol 2004; 40: 669-74.

  30. Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with a combination of pegylated interferon alfa 2b and ribavirin: an open label series. Transplantation 2004; 77: 190-4.

  31. Neff GW, Montalbano M, O’Brien C, Nishida S, Dafdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver transplant recipients with pegylated interferon alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303-7.

  32. Todd-Stravitz R, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850-8.

  33. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-67.

  34. Bizollon T, Admed SNS, Radenne S, Chevallier M, Chevallier P, Paraz P, et al. Long-term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut 2003; 52: 283-7.

  35. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199-207.




2020     |     www.medigraphic.com